Selinexor, Paclitaxel, and Carboplatin in Treating Patients with Advanced Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Inclusion Criteria

• Patients must have Memorial Sloan-Kettering Cancer Center (MSKCC) pathologically confirmed diagnosis of one of the following tumor types: * Ovarian, fallopian tube or primary peritoneal cancer * Ovarian carcinosarcoma * Endometrial cancer * Endometrial carcinosarcoma
• All patients with ovarian, fallopian tube or primary peritoneal cancer and ovarian carcinosarcoma must have recurrent disease, and only one prior line of chemotherapy that must have been platinum-based chemotherapy for the management of primary disease; this initial platinum-based treatment may have included intraperitoneal therapy, consolidation/maintenance and/or biologic/targeted agents (e.g., bevacizumab, poly adenosine diphosphate [ADP] ribose polymerase [PARP] inhibitor) as part of first-line treatment
• Patients with endometrial cancer or endometrial carcinosarcoma may either be chemotherapy naive or have had one prior line of chemotherapy that must have been a platinum-based chemotherapy regimen in the adjuvant or advanced/recurrent setting; the initial platinum-based treatment may have included consolidation/maintenance and/or biologic/targeted agents as part of first-line treatment; patients entering the trial chemotherapy naive must have stage IVB or recurrent disease and have disease that is not amenable to curative intent
• Patients must have measurable disease (RECIST 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be greater than or equal to 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray; lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI
• Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
• Platelets >= 100 x 10^9/L
• Hemoglobin >= 9 g/dL
• Creatinine =< 1.5 x upper limit of normal (ULN) or creatinine clearance >= 30 mL/min (Cockcroft-Gault calculation)
• Bilirubin =< 1.5 x ULN
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (less than or equal to 5 x upper limit of normal for patients with liver involvement of their cancer)
• Neuropathy (sensory and motor) less than or equal to grade 1
• Patients must have recovered from effects of recent surgery, radiotherapy, chemotherapy or biologic/targeted therapy to baseline or Common Terminology Criteria for Adverse Events (CTCAE) less than or equal to grade 1 (excluding alopecia or other non-clinically significant adverse events [AE's])
• Any hormonal therapy directed at malignant tumor must be discontinued at least one week prior to study treatment initiation
• Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted therapy and immunologic therapy, must be discontinued at least 3 weeks prior to study treatment initiation
• Any investigation agents must be discontinued at least 30 days prior to study treatment initiation
• Any prior radiation therapy must be discontinued at least 4 weeks prior to study treatment initiation
• At least 4 weeks must have lapsed since major surgery (e.g., laparotomy, laparoscopy, thoracotomy, video assisted thoracoscopy) prior to study treatment initiation
• Patients must be willing and able to swallow oral tablets
• Patients must have signed an approved informed consent and authorization permitting the release of personal health information
• Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; sexually active subjects must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug, even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug; pregnant women are excluded from this study

Exclusion Criteria

• Patients who are pregnant or nursing
• Patients who have had previous treatment with selinexor
• Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment
• Patients requiring drainage gastrostomy (e.g., drainage percutaneous endoscopic gastrostomy [PEG] tube) and/or parenteral hydration and/or nutrition
• Patients with clinically significant cardiovascular disease; this includes: * Uncontrolled hypertension, defined as systolic greater than or equal to 160 mm Hg or diastolic greater than or equal to 100 mm Hg despite antihypertensive medications * Myocardial infarction or unstable angina within 6 months prior to the first date of study treatment * New York Heart Association (NYHA) class II or greater congestive heart failure * History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication; this does not include asymptomatic atrial fibrillation with controlled ventricular rate * Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms; ** Note: if initial QTcF is found to be > 500 ms, two additional electrocardiograms (ECGs) separated by at least 3 minutes should be performed; if the average of these three consecutive results for QTcF is less than or equal to 500 ms, the subject meets eligibility in this regard
• Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
• Uncontrolled active infection requiring parenteral antibiotics, antivirals or antifungals within 1 week prior to the first date of study treatment
• Patients with macular degeneration, uncontrolled glaucoma or markedly decreased visual acuity